R60m seed to build the platform.
≈ US$3.2m · 25% equity · R180m pre-money · roughly 24 months of runway. Syndicated across a strategic consortium — banks, insurers, medical schemes and recoveries businesses.
Returns are illustrative and derived from the accompanying driver-based financial model. They are projections, not forecasts, and carry the uncertainty that word implies.
Investors who are also customers and data partners.
The R60m is syndicated across four cohorts that each gain from — and feed — the platform. Capital arrives with a balance sheet, a proprietary data set and a distribution channel attached.
Banks
Bring capital and transaction data; first buyers of verification, FICA and credit. Get cheaper offline KYC, thin-file underwriting and cover against FIC penalties.
Insurers
Bring capital plus claims and actuarial data; buyers of health, identity and fraud signal. Get predictive morbidity, a shared-value engine and a new mass market.
Medical schemes
Bring capital and consented clinical data; buyers of engagement and risk stratification. Get lower claims through prevention and sharper pricing.
Recoveries businesses
Bring capital plus repayment and recovery outcomes — the labels that train the models. Get propensity-to-pay scoring and contactability through the identity graph.
Driver-based, phased on this round plus a Series A in FY3.
P&L summary (R'm)
base case| Line | FY1 | FY2 | FY3 | FY4 | FY5 |
|---|---|---|---|---|---|
| Revenue | 8.7 | 43.2 | 126.2 | 282.8 | 533.4 |
| Gross margin | 53% | 60% | 66% | 71% | 74% |
| EBITDA | (12.5) | (13.5) | 9.0 | 75.5 | 201.9 |
EBITDA turns positive in FY3, alongside the Series A and the actuarially validated health engine. FY5 EBITDA margin is approximately 38%. Full driver detail sits in the accompanying model — assumptions, revenue build, cost build, cash flow and runway, and scenarios.
Illustrative consortium allocation
| Cohort | Indicative | Primary data contribution |
|---|---|---|
| Banks | R24m | Transaction & repayment behaviour |
| Insurers | R15m | Claims, actuarial & fraud signal |
| Medical schemes | R12m | Consented clinical & engagement data |
| Recoveries agencies | R9m | Recovery & propensity-to-pay outcomes |
| Total | R60m | 25% equity · R180m pre-money |
Governance preserves neutrality: the platform serves all participants on equal terms, no single cohort controls the board, and contributed data improves shared models under strict consent and purpose limitation — never resold as another participant's raw data.
Use of funds
Engineering and product · data, integrations and partnerships · go-to-market and sales · compliance, security and licensing · general and administrative plus working capital.
Seed MOIC — exit multiple × FY5 revenue
| EV/Rev | Bear −25% | Base | Bull +25% |
|---|---|---|---|
| 4.0× | 6.6× | 8.3× | 10.1× |
| 6.0× | 9.2× | 11.9× | 14.6× |
| 8.0× | 11.9× | 15.5× | 19.0× |
Exit paths: strategic acquisition by a global bureau, a payment network or a pan-African bank; or a financial sponsor, growth equity or public listing. Acquirers of alternative-data infrastructure have historically paid premium multiples. Illustrative — see the model.
The platform is not a deck.
Everything described here is running. The figures on this site are read from the live instance, the scorecard on the platform page executes the registered model, and the ledgers verify on request.
Live platform, right now
This page is provided in confidence for the purposes of evaluating an investment in Wynk Credit (Pty) Ltd. It is not an offer to sell or a solicitation of an offer to buy securities, and it is not a prospectus. Projections are illustrative and depend on assumptions that may not hold.